**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 68221

**Manuscript Type:** LETTER TO THE EDITOR

**Hepatocellular carcinoma biomarkers, an imminent need**

Zamora-León SP. Hepatocellular carcinoma biomarkers

S Pilar Zamora-León

**S Pilar Zamora-León,** Department of Preclinical Sciences, Faculty of Medicine, Universidad Católica del Maule, Talca 3460000, Chile

**Author contributions:** Zamora-León SP wrote the letter.

**Corresponding author: S Pilar Zamora-León, MSc, PhD, Academic Research, Assistant Professor,** Department of Preclinical Sciences, Faculty of Medicine, Universidad Católica del Maule, Avenida San Miguel 3605, Talca 3460000, Chile. pzamora@ucm.cl

**Received:** May 25, 2021

**Revised:** July 5, 2021

**Accepted:** September 19, 2021

**Published online:** November 15, 2021

**Abstract**

Hepatocellular carcinoma (HCC) is the most common malignant neoplasm of the liver and one of the deadliest cancers worldwide. The identification of novel, highly specific and more sensitive biomarkers for HCC is crucial because existing ones are deficient and non-confirmatory without histological biopsy or imaging techniques.

**Key Words:** Hepatocellular carcinoma; Biomarker; Blood; Urine; Feces; Gut microbiota

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zamora-León SP. Hepatocellular carcinoma biomarkers, an imminent need. *World J Gastrointest Oncol* 2021; 13(11): 1847-1849

**URL:** https://www.wjgnet.com/1948-5204/full/v13/i11/1847.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v13.i11.1847

**Core Tip:** The identification of specific, sensitive and validated biomarkers for hepatocellular carcinoma (HCC) is complex because of the variability in genetic profiles, but their requirement is urgent to achieve earlier detection of HCC. Body fluids and feces for biomarker detection constitute feasible and low cost screening tools for early diagnosis, prognosis and treatment of HCC.

**TO THE EDITOR**

I read the review by Guan *et al*[1], “Biomarkers for hepatocellular carcinoma based on body fluids and feces”, published in the April 2021 issue of the *World Journal of Gastrointestinal Oncology*, with profound interest.

Hepatocellular carcinoma (HCC) is the leading malignant neoplasm of the liver and one of the most common lethal cancers worldwide. For this reason, an early detection is crucial to decrease mortality, since symptomatology appears at later stages of the disease. The identification of novel, highly specific and sensitive biomarkers, or a combination of them, is of special concern because the existing ones are deficient and non-confirmatory without histological biopsy or imaging techniques. The utilization of body fluids and feces for biomarker detection constitutes a feasible minimally- or non-invasive and low-cost screening method that facilitates studies for early diagnosis, prognosis and treatment of HCC.

Since HCC can arise from a variety of etiological factors, such as metabolic disorders, virus infections or toxin exposure, the genetic profiles are considerably variable, resulting in diverse hepatic immune microenvironments. This implies that the metabolomic, proteomic and glycomic profiles should be better clarified for the various HCCs in order to improve overall understanding of the disease and allow for identification of appropriate and validated biomarkers[2].

Alpha-fetoprotein (AFP) is the most common biomarker utilized for HCC diagnosis, but its sensitivity is only 39%-65% and its performance at early stages of the disease is suboptimal. Therefore, to improve detection of the malignancy, AFP has to be combined with imaging findings as well as other parameters, such as age and sex, which increase the sensitivity. In addition, AFP-L3, the highest glycoform of AFP, has exhibited much higher sensitivity, and the AFP-L3/AFP ratio can be considered as a risk factor for the development of HCC[3].

Several metabolites have displayed higher accuracy than AFP, showing aberrant levels that can be detected at earlier stages of HCC[4]. Circulating tumor (ct)DNA also has great potential to became a biomarker, since it contains several tumor-specific mutations or epimutations, constituting a good approach for HCC detection and prognosis, and to serve as a tool for monitoring therapeutic response. Additionally, several different micro (mi)RNAs and other non-coding (nc)RNAs have been shown to be deregulated in HCC, implying that their aberrant expression should be evaluated and validated as potential prognostic biomarkers. Unfortunately, miRNA variabilities have been detected depending on whether they are measured in serum or plasma, thereby complicating interpretation[5-8].

Moreover, circulating tumor cells (CTCs) have shown partial sensitivity but high specificity and are considered to have great potential in prediction of recurrence and prognostic evaluation of HCC. On the other hand, extracellular vesicles (EVs), such as exosomes and microvesicles, the contents of which are very heterogeneous, do not present better diagnostic performances than CTCs or circulating cell-free DNA, but they do have good potential as future therapeutic agents[5,8,9].

The above-mentioned biomarkers, ctDNA, miRNAs, CTCs and EVs, are tumor-specific, which is of great advantage, because they exhibit the heterogeneity of the tumor and its evolution. These features cannot be detected with other plasma biomarkers.

Additionally, several urine molecules have the potential to be classified as biomarkers for prevention, detection, progression monitoring, and recurrence prediction of HCC[10]. It is possible that they can be used as auxiliary diagnostic tools in combination with AFP. Moreover, feces-based biomarkers, which reflect the gut microbiota — which is itself known to vary with different pathological stages, are under evaluation for their potential utility in early diagnosis, prognosis and progression monitoring of HCC. In addition, the use of antibiotics to modulate gut microbiota appears to be a favorable strategy to influence the progression of HCC. Promising results have also been obtained with probiotics in mouse HCC models, which have shown a reduction in the development of this malignant neoplasm, opening avenues of possible application as a therapy in humans in the future[11-13].

The identification of more specific and sensitive biomarkers for HCC, and their variability over time, is an urgent requirement due to their critical role for early detection and prognosis, for choosing appropriate therapy, or for use as a tool to follow-up the patient’s treatment response. Ideally, biomarkers should detect HCC months before the tumor is visible, to improve surveillance and facilitate initiation of an earlier therapy. Clearly, the identification of new biomarkers for prompt HCC detection is complex, nonetheless because of the diverse type of tumors (genetic heterogeneity). However, efforts must be made to combat this devastating tumor malignancy. Moreover, the performance of new biomarkers will have to be clinically validated to optimize the current therapeutical strategies.

**ACKNOWLEDGEMENTS**

I would like to thank the Faculty of Medicine and Universidad Católica del Maule for giving me the time to write this letter.

**REFERENCES**

1 **Guan MC**, Ouyang W, Wang MD, Liang L, Li N, Fu TT, Shen F, Lau WY, Xu QR, Huang DS, Zhu H, Yang T. Biomarkers for hepatocellular carcinoma based on body fluids and feces. *World J Gastrointest Oncol* 2021; **13**: 351-365 [PMID: 34040698 DOI: 10.4251/wjgo.v13.i5.351]

2 **Duan J**, Wu Y, Liu J, Zhang J, Fu Z, Feng T, Liu M, Han J, Li Z, Chen S. Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine. *J Hepatocell Carcinoma* 2019; **6**: 151-166 [PMID: 31696097 DOI: 10.2147/JHC.S224849]

3 **Daniele B**, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S108-S112 [PMID: 15508073 DOI: 10.1053/j.gastro.2004.09.023]

4 **Kim DJ**, Cho EJ, Yu KS, Jang IJ, Yoon JH, Park T, Cho JY. Comprehensive Metabolomic Search for Biomarkers to Differentiate Early Stage Hepatocellular Carcinoma from Cirrhosis. *Cancers (Basel)* 2019; **11** [PMID: 31590436 DOI: 10.3390/cancers11101497]

5 **Singh G**, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. *World J Hepatol* 2020; **12**: 558-573 [PMID: 33033565 DOI: 10.4254/wjh.v12.i9.558]

6 **Beudeker BJB**, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. *Therap Adv Gastroenterol* 2020; **13**: 1756284820931734 [PMID: 32647536 DOI: 10.1177/1756284820931734]

7 **De Stefano F**, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. *Dig Liver Dis* 2018; **50**: 1115-1123 [PMID: 30217732 DOI: 10.1016/j.dld.2018.08.019]

8 **Piñero F**, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. *Cells* 2020; **9** [PMID: 32492896 DOI: 10.3390/cells9061370]

9 **Chen W**, Mao Y, Liu C, Wu H, Chen S. Exosome in Hepatocellular Carcinoma: an update. *J Cancer* 2021; **12**: 2526-2536 [PMID: 33854614 DOI: 10.7150/jca.54566]

10 **Zhao Y**, Li Y, Liu W, Xing S, Wang D, Chen J, Sun L, Mu J, Liu W, Xing B, Sun W, He F. Identification of noninvasive diagnostic biomarkers for hepatocellular carcinoma by urinary proteomics. *J Proteomics* 2020; **225**: 103780 [PMID: 32298775 DOI: 10.1016/j.jprot.2020.103780]

11 **Ren Z**, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R, Xu S, Zhang H, Cui G, Chen X, Sun R, Wen H, Lerut JP, Kan Q, Li L, Zheng S. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. *Gut* 2019; **68**: 1014-1023 [PMID: 30045880 DOI: 10.1136/gutjnl-2017-315084]

12 **Rattan P**, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. *Liver Transpl* 2020; **26**: 1316-1327 [PMID: 32564483 DOI: 10.1002/lt.25828]

13 **Li E**, Lin L, Chen CW, Ou DL. Mouse Models for Immunotherapy in Hepatocellular Carcinoma. *Cancers (Basel)* 2019; **11** [PMID: 31731753 DOI: 10.3390/cancers11111800]

**Footnotes**

**Conflict-of-interest statement:** The author declares having no conflict of interest related to this letter.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review started:** May 25, 2021

**First decision:** July 4, 2021

**Article in press:** September 19, 2021

**Specialty type:** Oncology

**Country/Territory of origin:** Chile

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Tajiri K **S-Editor:** Gao CC **L-Editor:** A **P-Editor:** Li X



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**